Loading patent…
AssigneeThe Government of the United States of America, as represented by the Secretary of Homeland Security
InventorsMichael Puckette, Max V. Rasmussen
Estimating the term…
This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
A vaccine against foot-and-mouth disease virus (FMDV) comprising at least one FMDV viral protein selected from the group consisting of VP0, VP1, VP2, VP3, VP4 and FMDV virus-like particles (VLPs), the FMDV viral protein produced by a method comprising:
A pharmaceutical composition, comprising:
A method for inducing an immune response against foot-and-mouth disease virus (FMDV) in a subject, vaccinating a subject against FMDV, or reducing severity of an FMDV infection in a subject, comprising administering an effective amount of a composition comprising a FMDV viral protein to said subject, the FMDV viral protein selected from the group consisting of VP0, VP1, VP2, VP3, VP4 and FMDV virus-like particles (VLPs) and produced by a method comprising:
Dependencies are inferred from the claim text.